微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2021, Vol. 13 ›› Issue (5): 452-457.doi: 10.3969/j.issn.1674-5671.2021.05.02

• 肝癌专栏 • 上一篇    下一篇

基于增强子RNA建立肝细胞癌预后模型

  

  1. 空军军医大学西京消化病医院，肿瘤生物学国家重点实验室，国家消化系统疾病临床医学研究中心
  • 出版日期:2021-10-25 发布日期:2021-11-16
  • 通讯作者: 卢瑗瑗 E-mail：luyuandreamer@aliyun.com； 樊代明 E-mail：fandaim@fmmu.edu.cn
  • 基金资助:
    国家自然科学基金项目（81871913）；国家优秀青年科学基金项目（81822031）

Construction of a prognostic model of hepatocellular carcinoma based on enhancer RNA

  • Online:2021-10-25 Published:2021-11-16

PDF (PC)

171

赞

摘要： 目的 基于增强子RNA（enhancer RNA， eRNA）构建肝细胞癌（hepatocellular carcinoma，HCC）预后模型，并寻找理想的预后生物标志物。方法 利用癌症基因图谱（the Cancer Genome Atlas， TCGA）数据库eRNA表达谱和HCC患者临床数据筛选出关键eRNA，采用Lasso-Cox回归建立预后模型，以时间依赖性受试者工作特征（receiver operating characteristic， ROC）曲线评估模型区分度，并对关键eRNA进行生存分析和富集分析。结果 共筛选出27个关键eRNA。Lasso-Cox回归选定其中10个eRNA构建预后预测模型。时间依赖性ROC曲线1年、3年、5年的AUC分别为0.73、0.66、0.67。DCP1A与HCC患者预后显著相关，且与肿瘤状态、病理分级、临床分期相关（均P<0.05）。富集分析提示DCP1A主要位于细胞核内，通过发挥解旋酶、泛素化等活性，参与染色质修饰等生物学过程，且与癌症相关通路有关。结论 基于eRNA构建的预后模型可作为预测HCC患者生存的有效工具，DCP1A可能是HCC潜在的预后生物标志物。

关键词: 肝细胞癌, 增强子RNA, 预后, 生物信息学

Abstract: Objective To construct a prognostic model of hepatocellular carcinoma (HCC) based on enhancer RNA (eRNA), and identify the promising prognostic biomarker. Methods The expression profiles of eRNA and clinical data of HCC patients from the Cancer Genome Atlas (TCGA) database were downloaded to identify the key eRNAs. Lasso-Cox regression analysis was performed to construct the prognostic model. The time-dependent receiver operating characteristic (ROC) curve was used to evaluate the model discrimination, and survival analysis and enrichment analysis of key eRNA were performed. Results A total of 27 key eRNAs were screened out, of which 10 eRNAs were selected by Lasso-Cox regression to construct a prognostic prediction models. The AUC of time-dependent ROC curve at 1, 3 and 5 years were 0.73, 0.66 and 0.67, respectively. DCP1A was sinificantly associated with the prognosis of HCC patients, and was correlated with cancer status, pathological grade and clinical stage of HCC patients (all P<0.05). Enrichment analysis suggested that DCP1A was mainly located in the nucleus, participates in chromatin modification and other biological processes through the activities of helicase and ubiquitination, and was related to other cancer-related pathways. Conclusions The prognostic model based on eRNA can be used as an effective tool to predict the survival of HCC patients, and DCP1A may be a potential prognostic biomarker of HCC.

Key words: Hepatocellular carcinoma, Enhancer RNA, Prognosis, Bioinformatic

中图分类号: 

  • R735.37